ELVN Stock — Enliven Therapeutics Inc.: Cash, EV, Pipeline

Share price

$49.45

Market cap

$3,623.2M

Cash

$895.2M

Enterprise value

$2,728.0M

Balance sheet

Cash	$895.2M
Debt	$0.0M
Net cash	$895.2M
Enterprise value	$2,728.0M
Basic shares	73.3M shares
Fully diluted shares	87.2M shares
Fully diluted market cap	$4,314.3M
Cash per share	$12.21

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ELVN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	ELVN-002	Phase 1	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation	—
Feb 12 - Mar 26	ELVN-002	Phase 1	HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors	—
Jan 12 - Feb 23	ELVN-001	Phase 1	Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml	—
Feb 12 - Mar 25	ELVN-001	Phase 1	CML (Chronic Myelogenous Leukemia); Chronic Phase CML	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ELVN-001

Stage not disclosed · Active Modality: small molecule

Target BCR-ABL (ABL1)

Indications

Chronic Myeloid Leukemia (Phase 1)
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive (Phase 1)
Cml (Phase 1)

Status note Small molecule from the BCR-ABL program; preparations for a planned pivotal trial are underway. Indication and current trial stage not stated in the primary excerpts.

ELVN-002

Stage not disclosed · Terminated Modality: small molecule

Target HER2

Indications

HER2 Mutant Non-small Cell Lung Cancer (Phase 1)
HER2-positive Metastatic Breast Cancer (Phase 1)
HER2 Gene Mutation (Phase 1)

Status note The Company states it is exploring strategic alternatives for the ELVN-002 program and is no longer pursuing its development.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ELVN-002
Lead indication	HER2-positive Breast Cancer
Lead phase	Phase 1
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06328738	Phase 1	Active, not recruiting	Sponsor	ELVN	—	HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors	—
NCT05304377	Phase 1	Recruiting	Sponsor	ELVN	—	Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml	—
NCT06787144	Phase 1	Recruiting	Sponsor	ELVN	—	CML (Chronic Myelogenous Leukemia); Chronic Phase CML	—
NCT05650879	Phase 1	Active, not recruiting	Sponsor	ELVN	—	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Enliven Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	6,776,632	-1,182,906	6.51%	2026-08-14
Baker Bros. Advisors	905,191	no change	0.23%	2026-08-14
Logos Global Management	465,000	-75,000	1.02%	2026-08-14
ADAR1 Capital Management	387,718	+58,178	0.92%	2026-08-14
Ikarian Capital	126,541	+126,541	1.05%	2026-08-14
Sphera Biotech	112,765	-40,500	0.82%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ELVN — Enliven Therapeutics Inc.